Antidepressants: delving into resistance to enhance mood compliance

Major depressive disorder is a debilitating illness that affects more than 350 million people around the world. Medications and psychotherapy are effective for most people with depression. The most common treatments for depression are Selective Serotonin Reuptake Inhibitors (SSRIs), drugs such as Prozac that increase serotonin levels in some regions of the brain. Other SSRIs include citalopram (Celexa), escitalopram (Lexapro), sertraline (Zoloft), paroxetine (Pexeva) and vilazodone (Viibryd). About half of the patients who take the pills, however, do not respond to treatment. The reasons have not been completely understood; most scientists believe that other neurochemical mechanisms beside serotonin could be involved. Indeed, also dopamine, nor-epinephrine and GABA are neurotransmitters recognized to be involved in depression. A science team is thus trying to understand the molecular mechanisms of such treatment resistance. Ultimately, they would like to be able to predict which people will respond to antidepressant drugs before they begin treatment, and to develop new treatments that can circumvent antidepressant resistance among people who do not respond now to these drugs.

This is a research collaboration between the Neuroscience group at Columbia University Medical Center, where Rene Hen is an expert in basic and translational research and neuropsychiatric disorders; and the Functional Genomics group at Columbia Engineering, where Sergey Kalachikov is an expert in molecular biology, genomics, data analysis and statistics. They and other researchers have shown that an area of the brain called the hippocampal dentate gyrus plays a critical role in a person’s response to antidepressants. Dentate gyrus is part of the brain that is mainly responsible for learning and new memories and one of the few areas of the brain where new neurons are born during adulthood. Recently, while studying gene activity in neurons in the dentate gyrus, the team identified specific regulatory pathways and genes associated with the lack of response to antidepressant treatment. In particular, they found a strong association between treatment resistance and regulation of dendritic spines on the surface of neuronal cells that are responsible for connections between neurons. Dendritic spines are believed to be storage points of memories, like folders inside a computer hard disk.

Their chemistry is complicated and imply a network of hundreds of proteins and neurotransmitter cycles, in a entangled play among receptors, transporters and cellular protein platforms (scaffolding complexes). Moreover, 10 of the candidate genes found by the researchers are among the 13 genes associated with depression recently identified by a consortium team. That correlation of genes in both studies supports the team’s preliminary results, which is now using a combination of experimental approaches to pinpoint the mechanisms underlying resistance to antidepressants. Applying computational genomics, they will integrate several types of their own data with publicly available data on antidepressant resistance, including information on gene expression, behavior, and neuronal cell morphology. Then, using mice as animal models of depression, they will validate their predictions experimentally by monitoring the effect of antidepressants on the dendritic spines in the brains of the mice. The study will reveal targets for genetic manipulations for a future research project that will include single-cell analysis to find particular neuronal types in the brain that are involved in treatment resistance.

Dr. Kalachikov commented and concluded: “We feel very privileged to contribute to solving this problem. A plethora of regulatory pathways are involved, and there are difficulties in carrying out this kind of analysis at the level required for precision medicine. I hope that in a year or two we will have a good picture of what’s going on in critical areas of the brain, in the dentate gyrus in particular, that prevent antidepressants from working in half the people who try them, and that we will be able to predict genetic mechanisms in the body that can be targeted by antidepressants. If we succeed, these new targets and treatments could allow millions of people to lead healthier and happier lives”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Oh SJ, Cheng J, Jang JH et al. Mol Psychiatry 2019 Mar 5. 

Vadodaria KC et al., Gage FH. Mol Psychiatry. 2019 Jan 30.

Glover ME, McCoy CR et al. Eur J Neurosci. 2018 Dec 26.

Micheli L et al. Neuropharmacology. 2018 Oct; 141:316-330.

Informazioni su Dott. Gianfrancesco Cormaci 1365 Articoli
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry specialty in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Detentore di un brevetto sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of a patent concerning the production of bakery gluten-free products, starting from regular wheat flour). - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica, salute e benessere sui siti web salutesicilia.com e medicomunicare.it